Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Carotid endarterectomy and stenting including TCAR. Main billing specialty: vascular surgery.
Medicare fee-for-service carotid revascularization cases in the 46 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 67 | 3,226−2.7%/yr | −2.7%/yr | 1.41.3× | 0% | 3,330 in 2030+0.5%/yr |
| Texas | 54 | 3,080−4.9%/yr | −4.9%/yr | 1.41.3× | 0% | 3,370 in 2030+1.5%/yr |
| California | 46 | 2,550−2.4%/yr | −2.4%/yr | 0.70.7× | 0% | 2,560 in 2030+0.1%/yr |
| Pennsylvania | 23 | 1,666−3.1%/yr | −3.1%/yr | 1.21.1× | 0% | 1,760 in 2030+0.9%/yr |
| New York | 32 | 1,508−6.4%/yr | −6.4%/yr | 0.80.7× | 0% | 1,510 in 20300%/yr |
| Illinois | 31 | 1,439−3.9%/yr | −3.9%/yr | 1.00.9× | 0% | 1,600 in 2030+1.8%/yr |
| Ohio | 18 | 1,238−6.8%/yr | −6.8%/yr | 1.11.0× | 0% | 1,200 in 2030−0.6%/yr |
| Georgia | 20 | 1,108−4.6%/yr | −4.6%/yr | 1.31.1× | 0% | 1,310 in 2030+2.8%/yr |
| New Jersey | 26 | 1,073−1.9%/yr | −1.9%/yr | 1.00.9× | 0% | 1,090 in 2030+0.2%/yr |
| Tennessee | 23 | 1,070−7.3%/yr | −7.3%/yr | 1.51.3× | 0% | 1,090 in 2030+0.3%/yr |
| Virginia | 28 | 1,070−3.9%/yr | −3.9%/yr | 1.00.9× | 0% | 1,290 in 2030+3.1%/yr |
| Missouri | 24 | 999−5.5%/yr | −5.5%/yr | 1.61.4× | 0% | 1,110 in 2030+1.7%/yr |
| Massachusetts | 18 | 984−3.3%/yr | −3.3%/yr | 1.00.9× | 0% | 1,170 in 2030+2.9%/yr |
| Michigan | 13 | 961−9.4%/yr | −9.4%/yr | 1.11.0× | 0% | 870 in 2030−1.7%/yr |
| Indiana | 20 | 960−7.3%/yr | −7.3%/yr | 1.31.2× | 0% | 930 in 2030−0.5%/yr |
| North Carolina | 17 | 916−10%/yr | −10%/yr | 0.90.8× | 0% | 940 in 2030+0.4%/yr |
| Maryland | 19 | 887+1.4%/yr | +1.4%/yr | 1.00.9× | 0% | 950 in 2030+1.2%/yr |
| Arizona | 21 | 884−3%/yr | −3%/yr | 1.21.0× | 0% | 1,070 in 2030+3.3%/yr |
| Kentucky | 15 | 796−5.1%/yr | −5.1%/yr | 1.71.5× | 0% | 760 in 2030−0.8%/yr |
| Oklahoma | 16 | 757−4.9%/yr | −4.9%/yr | 1.51.4× | 0% | 700 in 2030−1.3%/yr |
| South Carolina | 14 | 710−8.3%/yr | −8.3%/yr | 1.00.9× | 0% | 840 in 2030+2.9%/yr |
| Louisiana | 17 | 665−8.6%/yr | −8.6%/yr | 1.61.4× | 0% | 580 in 2030−2.4%/yr |
| Washington | 15 | 658−6.5%/yr | −6.5%/yr | 0.80.8× | 0% | 680 in 2030+0.6%/yr |
| Wisconsin | 15 | 618−4.6%/yr | −4.6%/yr | 1.11.0× | 0% | 730 in 2030+2.8%/yr |
| Alabama | 13 | 603−11%/yr | −11%/yr | 1.31.2× | 0% | 600 in 2030−0.2%/yr |
| Arkansas | 13 | 532−8.8%/yr | −8.8%/yr | 1.41.2× | 0% | 550 in 2030+0.4%/yr |
| Kansas | 16 | 530−3.8%/yr | −3.8%/yr | 1.31.2× | 0% | 600 in 2030+2%/yr |
| Mississippi | 11 | 448−8.8%/yr | −8.8%/yr | 1.21.1× | 0% | 340 in 2030−4.7%/yr |
| Oregon | 8 | 425−4.9%/yr | −4.9%/yr | 1.00.9× | 0% | 460 in 2030+1.4%/yr |
| Minnesota | 6 | 404−8.6%/yr | −8.6%/yr | 0.90.8× | 0% | 530 in 2030+4.6%/yr |
| West Virginia | 5 | 402−5.6%/yr | −5.6%/yr | 1.91.7× | 0% | 380 in 2030−1%/yr |
| Iowa | 11 | 376−4.9%/yr | −4.9%/yr | 0.80.7× | 0% | 380 in 2030+0.3%/yr |
| Connecticut | 1 | 337−3.8%/yr | −3.8%/yr | 1.00.9× | 0% | 320 in 2030−1%/yr |
| Nebraska | 5 | 321−9.6%/yr | −9.6%/yr | 1.21.1× | 0% | 410 in 2030+4.2%/yr |
| South Dakota | 10 | 315+2.9%/yr | +2.9%/yr | 2.42.1× | 0% | 470 in 2030+6.9%/yr |
| Nevada | 11 | 315−0.4%/yr | −0.4%/yr | 1.11.0× | 0% | 610 in 2030+11%/yr |
| Colorado | 5 | 302−7.5%/yr | −7.5%/yr | 0.60.5× | 0% | 280 in 2030−1.5%/yr |
| New Hampshire | 4 | 267−3.3%/yr | −3.3%/yr | 1.21.0× | 0% | 360 in 2030+5.1%/yr |
| Idaho | 7 | 243+15%/yr | +15%/yr | 1.21.0× | 0% | 590 in 2030+16%/yr |
| Delaware | 10 | 186−2.9%/yr | −2.9%/yr | 1.11.0× | 0% | 180 in 2030−0.6%/yr |
| Utah | 2 | 170−2.8%/yr | −2.8%/yr | 0.80.7× | 0% | 110 in 2030−6.4%/yr |
| Montana | 4 | 162−1.2%/yr | −1.2%/yr | 0.80.8× | 0% | 170 in 2030+1.3%/yr |
| Maine | 0 | 161−5.5%/yr | −5.5%/yr | 1.00.9× | 0% | 670 in 2030+27%/yr |
| Rhode Island | 3 | 142+2.9%/yr | +2.9%/yr | 1.51.4× | 0% | 70 in 2030−11%/yr |
| North Dakota | 3 | 119−14%/yr | −14%/yr | 1.21.1× | 0% | 380 in 2030+21%/yr |
| New Mexico | 1 | 111−8.3%/yr | −8.3%/yr | 0.50.4× | 0% | 150 in 2030+5.6%/yr |
Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 144 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 8 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Boston Scientific | 44 |
| Medtronic | 33 |
| Abbott | 28 |
| Cordis | 20 |
| Contego Medical | 9 |
| W L Gore & Associates | 4 |
| Inspiremd | 3 |
| Microvention | 3 |
Product codes: NIM (stent, carotid). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 29% of the cases CMS names in Florida; 46 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Peripheral arterial intervention | 1,321 | 182,726−5.9%/yr | −5.9%/yr | 215,300 in 2030+2.8%/yr |
| Superficial venous ablation | 1,980 | 166,794−4.1%/yr | −4.1%/yr | 191,600 in 2030+2.3%/yr |
| Dialysis access | 1,721 | 161,268−13%/yr | −13%/yr | 158,700 in 2030−0.3%/yr |
| Thrombectomy, IVC filters & venous stents | 389 | 47,332+0.1%/yr | +0.1%/yr | 62,700 in 2030+4.8%/yr |
| Aortic endografts (EVAR/TEVAR) | 89 | 13,204−6.8%/yr | −6.8%/yr | 13,800 in 2030+0.7%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 8 companies reported engagement with surgeons in the covered states worth $2.8M in consulting, speaking, meals and travel tied to these products, about $3,787 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.